Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al
- PMID: 28483346
- DOI: 10.1016/j.maturitas.2017.04.019
Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al
Comment on
-
Bisphosphonates or denosumab discontinuation and risk of fractures.Maturitas. 2017 Aug;102:75. doi: 10.1016/j.maturitas.2017.04.016. Epub 2017 Apr 27. Maturitas. 2017. PMID: 28495014 No abstract available.
-
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.Maturitas. 2017 Jul;101:23-30. doi: 10.1016/j.maturitas.2017.04.008. Epub 2017 Apr 15. Maturitas. 2017. PMID: 28539165
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
